






Soy-based infant formulas have been available for nearly one hundred years and more than 20 million American infants have been fed soy-based infant formulas since the 1970s. Currently, soy-based infant formulas account for approximately 25 percent of the formulas marketed in the United States. Although the present recommendations for soy-based infant formulas used in the United States are likely still valid, the public health significance of the safety of soy-based infant formulas receives a great deal of attention. Infants fed with soy-based infant formulas are exposed to substantial levels of soy isoflavones, which are phytoestrogens with potential hormonal activity due to their chemical similarity to endogenous estrogen. Isoflavones possess weak estrogenic activity and could theoretically negatively affect endocrine development. This has led researchers to study the health effects of isoflavones in soy-based infant formulas on thyroid functions. This literature review discusses previous animal and human studies and provides suggestions for further studies in the research of isoflavones in soy-based infant formulas and effects on thyroid function. 
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1.	Introduction
Soy-based infant formulas, a kind of infant food made using soy protein and other components, have been used throughout the world for nearly one hundred years [1]. According to recent data, the prevalence of soy-based infant formulas feeding is approximately 20-25% in Canada [2] and the United States [3], which is a bit higher than in Australia [4] and the United Kingdom (18-22%) [5]. Nowadays, the presence of phytoestrogens in the form of isoflavones in soy and the related safety of soy-based infant formulas receive a great deal of attention. Isoflavones are phytochemicals found in the soybean plant, which possess weak estrogenic activity and could theoretically negatively effect endocrine and reproductive development [1]. Previous studies have shown that despite soy isoflavones being only weakly estrogenic, the levels of serum isoflavones in infants fed with soy-based infant formulas are extremely high and remain of concern. Four-week-old infants are thought to digest, absorb, and excrete isoflavones from soy-based infant formulas as effectively as adults consuming soy products do [6]. Although there is some support for the use of soy isoflavones in preventing hormone-related conditions in adults [7], whether the soy-based infant formulas are safe for infant use has been extensively debated. 
Several studies have investigated the early exposure to soy isoflavones and their potential negative health effects on sexual development and reproduction, neurobehavioral development, immune function, and thyroid function [7]. In this essay, selected studies, focusing on the health effects of isoflavones in soy-based infant formulas on thyroid function, will be discussed. Although the present recommendations for soy-based infant formulas used in the United States are likely still valid [8], further relevant research is suggested. In addition, parents should pay more attention to the choice of their babies’ formulas.
2.	SOY-BASED INFANT FORMULAS
Soy-based infant formulas are a kind of infant food made using soy protein and other components. For nearly a century, soy-based infant formulas have been available throughout the world and fed to millions of infants worldwide [1]. According to the American Academy of Pediatrics, in spite of the limited indications, the prevalence of soy-based infant formulas feeding has nearly doubled during the past decades and accounted for approximately 25 percent of the formula market in the United States [9]. In other words, since the 1970s when the modern soy-based infant formulas began to be marketed, more than 20 million American infants have been fed soy-based infant formulas [8].
2.1   History of Soy-based Infant Formulas
The first report about soy-based infant formulas feeding was published in 1909 [10]. In the 1920s, Hill and Stuart recommended soy for infantile eczema [10]. Then the first commercial soy-based infant formulas, which contained soy flour as the protein source, were introduced in 1929. Compared to current soy-based infant formulas, the early soy flour-based formulas had several nonprotein components including soy carbohydrates, fibers, phytates, and protease inhibitors, which are largely absent from current formulas. The development of soy protein isolate, a purified, high-quality, highly digestible soy protein, was stimulated because of the limitation of soy flour-based formulas. In the mid-1960s, soy protein isolate replaced the soy flour and became the primary soy protein source in soy-based infant formulas worldwide [10]. In the following decades, manufacturers added supplementary nutrients to the standard soy-based infant formulas and met the recommendations by the American Academy of Pediatrics, the requirements for term infants in Infant Formula Act of 1980, and the quality factors of supporting normal growth and having a high protein-efficiency ratio by the United States Food and Drug Administration [9].
2.2   Composition of Soy-based infant formulas
According to the American Academy of Pediatrics, currently available soy-based infant formulas are all free of cow’s milk protein and lactose and provide 67 kcal/dL. They are all iron-fortified and meet the specifications of vitamin, mineral, and electrolyte for feeding term infants given in the 2004 American Academy of Pediatrics guidelines. The protein content is 2.45 to 2.8 g per 100 kcal or 1.65 to 1.9 g/dL, obtained from the soy isolate supplemented with L-methionine, L-carnitine, and taurine; the fat content ranges from 5.02 to 5.46 g per 100 kcal or 3.4 to 3.6 g/dL, derived primarily from vegetable oils, including soy, palm, sunflower, olein, safflower, and coconut; the carbohydrate content ranges from 10.26 to 10.95 g per 100 kcal or 6.9 to 7.4 g/dL, existed in corn maltodextrin, corn syrup solids, and sucrose. In addition, docosahexaenoic and arachidonic acids, iron, and zinc are added routinely [9].
2.3   Reasons for Choosing Soy-based Infant Formulas
Among parents, there are three common reasons for choosing the soy-based infant formulas instead of cow’s milk-based formula. Since soy-based infant formulas is free of milk protein and lactose, parents usually choose it when their baby is sensitive, or allergic to milk protein, or when a baby is having trouble digesting lactose or milk sugar [10]. In addition, since there are no completely vegan baby formulas, the soy-based infant formulas can be a choice when a parent wishes to raise their baby as a vegetarian but is not breastfeeding. Finally, parents usually switch to soy-based infant formulas when their baby demonstrates irritability, emesis, or colic when consuming cow’s milk-based formula in hopes of relieving such symptoms [9].
Despite these common reasons for use, the American Academy of Pediatrics claims that the only needs for soy-based infant formulas use are congenital galactosemia, hereditary lactase deficiency, or strict veganism. As for infants with documented cow’s milk protein sensitivity or allergy, research shows that 10 to 14 percent of them will also be allergic to soy protein. In addition, studies comparing cow’s milk-based and soy-based infant formulas demonstrate that soy-based infant formulas does not decrease the risk of infant colic. The American Academy of Pediatrics states that there is no proven value of routine use of soy-based infant formulas in the prevention and management of colic, or fussiness, or atopic disease among infants [9].
3.	ISOFLAVONES IN SOY-BASED INFANT FORMULAS
The composition of soy-based infant formulas has developed throughout its one hundred year history around the world and the safe use of soy-based infant formulas continues to be debated extensively. In recent decades, isoflavones present in soy-based infant formulas become of concern due to emerging studies on the potential negative effects of isoflavones on sexual development and reproduction, neurobehavioral development, immune function, and thyroid function [8].
3.1   Composition of Isoflavones
Isoflavones, water-soluble chemicals found in many plants, are a subgroup of phytoestrogens, which are plant-derived xenoestrogens and are not generated within the endocrine system. Phytoestrogens are called estrogen-like molecules or non-steroidal estrogens because their structures are very similar to 17-β-estradiol, which is a kind of hormone estrogen in the body (Fig. 1). Based on the chemical structure, phytoestrogens are divided into four groups, including isoflavones, lignans, coumestans, and stilbens [11]. Undoubtedly, isoflavones are chemically similar to endogenous estrogen [12]. In the environment, isoflavones occur in more than three hundred kinds of plants, primarily in legumes such as soybean [11, 12]. There are four main kinds of isoflavones in the diet, including genistein, daidzein, biochanin A, and formononetin [12]. Among these four kinds, genistein and daidzein are the two principal isoflavones in soy-based infant formulas. Genistein is considered the most abundant but not the only active soy isoflavones in soy-based infant formulas, which accounts for nearly 67.1% of the total isoflavone content. The other one, daidzein, accounts for approximately 28.7% of total isoflavones [1].


Figure 1. Molecular structure of 17-β-estradiol, isoflavones genistein and daidzein [7]
3.2 Exposure to Isoflavones in Soy-based infant formulas
Previous studies tested the levels of isoflavones in five different soy-based infant formulas and found that the levels varied from 32 to 47 mg/L [13,14]. Thus, in the four months after birth infants being fed these formulas are being exposed to approximately 5.7-11.9 mg isoflavones/kg body weight. However, adults with soy rich diets are on average being exposed to only 0.71 mg isoflavones/kg body weight (based on a body weight of 70 kg) [15]. Based on this data, the infants are exposed to 6 to 11 times more isoflavones than adults as determined by body weight. In addition, the circulating levels of isoflavones are 13,000 to 22,000 times greater than the circulating levels of 17-β-estradiol among these infants [13].
3.3   Metabolism of Isoflavones
R.L. Divi concludes in a 1997 study “following ingestion of isoflavone-rich foods, isoflavones were hydrolyzed in the intestinal tract, absorbed in the small intestine and possibly the colon in deconjugated forms, and then undergo conjugation by hepatic enzymes, followed by biliary and urinary excretion” [16]. The hydrolysis and deconjugation of isoflavones in the intestinal tract depends on the presence of intestinal enzymes as well as bacteria. Isoflavones are degradated in the liver by conjugating with glucuronic acid and to a lesser degree with sulfates, then excreted from the body in the urine or bile within 24 hours [11]. After biliary excretion into the intestinal tract, isoflavones can be deconjugated again, reabsorbed, and further metabolized. Thus, in blood serum, the isoflavones could circulate in the unconjugated and conjugated forms and reach the highest level within 2-8 hours after consumption [11]. Four-week-old infants can apparently digest, absorb, and excrete isoflavones from soy-based infant formulas as effectively as adults [6].
3.4   Mechanism of Isoflavones Action
Estrogen receptors are a group of proteins found in certain cells in the body. They are the special sites that allow estrogen to attach and activate the estrogenic effects in the cell. Isoflavones are able to bind to estrogen receptors due to their structural similarity to endogenous estrogen [11]. Although isoflavones can latch onto estrogen receptors, they possess weak estrogenic activity. According to the summary by K.O. Klein in 1998, the potency of principal soy isoflavones is 10,000 to 140,000 times lower in animal and in vitro models than estradiol is, which is the major endogenous estrogen in humans (Table 1) [12]. Under different conditions, isoflavones could have either positive or negative effects on the body. When there is not enough estrogen in the body, the cells with estrogen receptors will be stimulated by isoflavones, which will partially make up for the estrogen deficiency. Conversely, when there is plenty of estrogen, the real estrogen may be blocked by isoflavones from attaching to estrogen receptors, thereby the net estrogenic effect will be reduced. Therefore, when binding to estrogen receptors, isoflavones could stimulate the production of sex hormone-binding globulin, as well as inhibit enzymes such as tyrosine protein kinase and estrogen synthetase. Moreover, among different species and different target organs and at different ages, the likely mechanisms for isoflavones’ actions are probably different [12].

Table 1. Relative potency of principal isoflavones in soy as compared with estrogens [12]
Main Endogenous EstrogensEstradiol                                                                             1Estrone                                                                            0.5
Principal Isoflavones in SoyGenistein                                                       0.0001-0.0008Daidzein                                                  0.000007-0.00002

4.	EFFECTS ON THYROID FUNCTION
4.1   Introduction of Thyroid
4.1.1   Thyroid Gland Function
In humans, the thyroid is a butterfly shaped gland located in the lower part of the neck and enfolded around the front of the trachea [17]. The primary function of the thyroid gland is producing thyroid hormones – calcitonin, triiodothyroine (T3), and thyroxine (T4) – which takes place in the thyroid follicles [18]. The thyroid hormones can regulate several metabolic processes, therefore they are very important in numerous aspects in humans, such as normal growth, development and maturation of the central nervous system, the cardiovascular system and the skeleton [17].  
Thyroid function in humans can be adversely affected by common environmental exposures [19]. Isoflavones, in particular, genistein and daidzein, as one of the environmental exposures, can lead to inactivation of thyroid peroxidase (TPO), thereby inhibiting thyroid hormone formation, which will be discussed in the following sections. Since the thyroid hormone is critical and necessary for normal development in utero and in infancy [19], the effects of isoflavones exposure from soy-based infant formulas on thyroid function should be of particular concern. 
4.1.2   Biosynthesis of Thyroid Hormones
Thyroid peroxidase (TPO), an enzyme normally found in the thyroid gland, plays an important role in the production of thyroid hormones. Studies show that there are two actions catalyzed by TPO in the process of thyroid hormone synthesis (Fig. 2). The first step is the iodination of tyrosyl residues on thyroglobulin. The second step is the subsequent oxidative coupling, producing T3 and T4 [17].


Figure 2. Proposed mechanism for TPO catalyzed thyroxine synthesis [25]
4.1.3   Thyroid Hormones Effected by Iodine
Iodine is an essential component of both T4 and T3. Iodine deficiency is associated with lower thyroid hormone production [20]. V.R. Preedy et al. state in the book < Isoflavones: Chemistry, Analysis, Function and Effects > “When serum iodine levels are low or the thyroid is not able to incorporate enough iodine, the anterior pituitary secretes a hormone called thyroid stimulating hormone (TSH). When in excess, the secretion of TSH compensates by increasing the size of the thyroid and thereby allowing the gland to work more efficiently” [17]. However, excess iodine can also affect the thyroid adversely, which depends on underlying thyroid function, the extent and duration of iodine excess [20].
4.2   Review of Animal Studies
Studies have shown that enlargement of the thyroid is caused by a soy diet and inhibited by an iodine-added diet in rats [21]. In recent years, many additional rodent studies have been conducted on the effects of soy and isoflavones on thyroid function.
In 1997, R.L. Divi et al. published a study on the characterization and anti-thyroid mechanisms in vitro of isoflavones from soybeans. This study shows that the isoflavones genistein and daidzein inhibit TPO-catalyzed iodination and coupling [22]. In the absence of iodide, genistein and daidzein cause time-dependent and irreversible inactivation of TPO, which was observed in the heme visible spectrum with dramatic changes. Under conditions of iodine deficiency, isoflavones could covalently combine with iodide and produce iodinated products, thereby, enzymatic oxidation of isoflavones increase and intrathyroidal iodide levels decrease. Subsequently, the activity of TPO was inhibited [22]. A proposed mechanism for inhibition of TPO by soy isoflavones is shown in this study (Fig. 3).  R.L. Divi et al. demonstrated that “the scheme shows the ways in which genistein can intercept reactive enzyme intermediates (i.e. TPO compound I, the protein radical form of TPO com- pound II and the TPO iodinating species) involved in the iodination and coupling reactions required for thyroxine synthesis. Reaction of compound I with isoflavones would produce a reactive isoflavone radical at the active site along with a radical form of compound II, which could combine to form inactivated enzyme presumably through covalent modification of active site amino acid residues” [22].


Figure 3. Proposed mechanisms for inhibition of TPO by soy isoflavones [25]

In the following years, studies were conducted to assess the effects of dietary genistein on TPO and hypothyroidism both in vitro and vivo. In the in vitro study, incubation of purified bovine TPO, porcine TPO, rat microsomal TPO, and human TPO with genistein (10 μM) and H2O2 (100 μM) for 5 minutes produced activity losses of 53 ± 3, 40 ± 6, 66 ± 7, and 62 ± 3%, respectively (mean ± SD) [21]. Based on these findings, it may be suggested that isoflavone-mediated inactivation of TPO is a general phenomenon across mammalian species. In the in vivo study, rat pups were born to dams fed with genistein at 0, 5, 100, and 500 ppm and continued on a genistein-supplemented diet to the postnatal twentieth week. The genistein levels in serum and thyroid were detected by HPLC with mass spectrometry and the TPO activity was measured spectrophotometrically. The results showed that: 1) the levels of serum genistein in female rats were a little higher than in male rats; 2) the increasing levels of genistein in thyroid tissue were significantly dose-dependent; 3) the TPO activity in rats was decreased by up to 80% in a dose-dependent manner; and 4) the TPO activity in rats with a soy-based diet was nearly 50% lower than in rats with a soy-free diet [21]. In addition, the data in this study showed that the level of genistein in rat thyroid tissue was sufficient for inactivation of rat TPO in vitro, which confirms that the inhibition of TPO is due to enzyme inactivation and the proposed mechanisms described in the previous study [22]. However, there were no differences of thyroid hormone levels in serum, thyroid weights, or histopathology between soy-based and soy-free diet groups, which indicates that although the TPO inactivation increaseed with the soy isoflavone consumption, the remaining enzymatic activity in normal rats was sufficient to maintain thyroid homeostasis in the absence of additional perturbations [21].
Takako Ikeda et al. investigated the possible synergism ability of soybean intake with iodine deficiency on the thyroid hyperplasia in rats [23]. In this study, rats were separated into four groups and fed either a 20% gluten diet (Group 1), an iodine-deficient gluten diet (Group 2), a 20% defatted soybean diet (Group 3), or an iodine-deficient defatted soybean diet (Group 4). The results showed that: 1) the thyroid gland weights in Group 2 and Group 4 were significantly higher than in Group 1; 2) the levels of serum T4 in Group 2 and Group 4 were significantly lower than in Group 1; 3) the levels of TSH in Group 3 and Group 4 were significantly higher than in Group 1; and 4) discernible diffuse follicular hyperplasia of thyroid was observed in Group 4. These results suggest that the synergism of defatted soybean diet and iodine deficiency could cause thyroid hyperplasia in rats [23]. Subsequently, this group conducted another study in rats to evaluate the synergism effects of isolated soy isoflavones with iodine deficiency on thyroid hyperplasia [24]. These more recent findings suggest that under the conditions of iodide deficiency, the isolated soy isoflavones were not sufficient to cause thyroid hyperplasia in rats. Therefore, the goitrogenic effects may be caused by the synergistic action of isoflavones-mediated TPO inhibition and unknown factors of soy in iodine-deficient rats [25].
4.3   Review of Human Studies
4.3.1   Goitrogenic Effects of Isoflavones
In the early 1960s, there were several case reports about goiters occurring in infants on soy formulas [26]. After the infants changed to a cow’s milk formula, the thyroid enlargement was resolved [8].  At that time, the protein source in soy formulas was soy flour. In the mid-1960s, the soy flour-based formula was replaced by “modern soy formula”, which was made from soy protein isolate and fortified with iodine. Since then, no further documented cases of soy-infant-formula-induced goiters have been reported. The mechanism explaining this phenomenon is that an increased iodine requirement after T4 depletion from increased fecal wastage could result in the high-uptake goiters [27]. 
However, in the mid-1990s, a case of a full-term male infant with congenital hypothyroidism on soy-based infant formulas was reported [27]. This infant was fed soy-based formulas from birth because of his family history of intolerance of cow’s milk. His thyroid tests showed a lack of TSH suppression and he was insensitive to levothyroxine (L-T4) treatment while consuming soy-based infant formulas. But after changing from the soy-based infant formulas to the cow’s milk formulas, his thyroid tests showed a significant suppression of TSH and his thyroid function continued to normalize over time while he received the same or lower dose of L-T4. This case called attention to the effects of soy diets on thyroid function, particularly in hypothyroid infants receiving the thyroid hormone [27]. 
Also in the 1990s, Muhammad et al. conducted a study to evaluate the relationship between soy-based infant formulas feeding and abnormalities in thyroid function tests in three infants with congenital hypothyroidism [28]. These infants were treated with recommended doses of L-T4 and followed monthly for three months and twice monthly thereafter to test the T4 and TSH levels. The results show that the treatment doses of L-T4 should be increased when the infants with congenital hypothyroidism are fed soy-based infant formulas; conversely, the treatment doses of L-T4 should be decreased when the soy-based infant formulas feeding is discontinued. This study and other related studies also reveal the effect of composition of infant formulas on serum thyroxin level [28, 29].
In recent years, S.C. Conrad et al. studied whether feeding soy-based infant formulas to infants with congenital hypothyroidism would cause the prolonged increase of TSH through a retrospective analysis of patient records [30].  The 78 subjects were separated into either the soy or non-soy diet group. Eight of them were in the soy-based formula group and the rest 70 were in the non-soy-based formula group. The reviewed data included clinical diagnosis, date of treatment initiation, TSH, L-T4 dose, weight, length, and diet information. The results of the data analysis showed that there was a significant difference between the two groups regarding time to TSH normalization, first TSH on treatment, percentage with increased TSH at 4 months of age, percentage with increased TSH throughout the first year of life, and in the overall trend of TSH at each visit. Based on these results, the authors pointed out that the infants with congenital hypothyroidism fed on soy-based formulas had a more prolonged increase of TSH than those fed on non-soy-based formulas. There were two potential mechanisms explaining this phenomenon. First, it may be related to malabsorption and increased fecal loss of L-T4 because subjects who were fed by soy-based infant formulas perhaps had some problems with malabsorption that was triggered by the soy-based formulas. Second, since it has been proven that the isoflavones could inhibit the catalytic activity of TPO, thereby, inhibiting thyroid hormone formation, soy may be acting on the thyroid gland as a goitrogen directly [30].
Moreover, J. Milerova and co-workers investigated the correlation between isoflavones levels and thyroid laboratory parameters in 268 children, who did not have overt thyroid diseases. All of these children were screened for iodine deficiency in one region of the Czech Republic. The results showed that a significant correlation between circulating isoflavone concentrations in blood and thyroid function in the subgroup of 36 children who ate soy food in the previous 24 hours; however, there was only a modest association between isoflavones serum levels and parameters of thyroid function in a population of 268 children [31].
4.3.2   Isoflavones and Autoimmune Thyroid Disease
A case control study of teenaged children with autoimmune thyroid disease was conducted to assess whether feeding formulas in early life was associated with the subsequent development of autoimmune thyroid disease [32]. The subjects in this study included 59 children with autoimmune thyroid disease, 76 healthy siblings, and 54 healthy nonrelated control children. Researchers collected information through telephone interview and analyzed data by 2 × 2 chi-square tests. The results showed that the frequency of using soy-based infant formulas in early life was significantly higher in teenaged children with a diagnosis of autoimmune thyroid disease (18 out of 59, 31%) than in healthy siblings (nine out of 76, 12%) and control group children (seven out of 54, 13%); however, there were no differences among these three groups with respect to breastfeeding. Therefore, it was concluded that there may exist an association of using soy-based infant formulas in early life and autoimmune thyroid disease [32]. There were two possible explanations. Firstly, the prevalence of gastrointestinal alterations and/or cow’s milk formula intolerance is higher in children with autoimmune thyroid disease than in the healthy groups. Secondly, a number of environmental exposures confer an increased risk of autoimmune thyroid disease [19]. Isoflavones, one of the environmental agents, inhibit TPO activity and then, possibly, increase thyroid hormone, which could act as a trigger or accelerate autoimmune thyroid disease [19].
5.	CONCLUSIONS
5.1   Summarizations and Critique of Studies
Overall, in vitro and in vivo animal studies have proven that isoflavones could exert inhibition of TPO, provide potential explanatory mechanisms [22], and suggest the isoflavones in soy—not the only isolated isoflavones—may have putative goitrogenic effects [23, 24]. However, the synergic goitrogenic effects of isoflavones-mediated TPO inhibition and some potential factors in soy have not been illustrated because the potential factors are unknown. Although these animal studies used rats, mice, and piglets, which may have similar absorption and metabolism of soy isoflavones to human infants, data presenting in vitro and in vivo animal studies are not easy to translate to humans [1]. Moreover, in some animal studies, isolated soy isoflavones were used instead of the mixture form of isoflavones found in soy-based infant formulas. In such situations, the data and results could be a little different than soy-based feeding with real formulas. In addition, the infants and children’s studies are very limited and the goiterogenic effects of isoflavones have not been substantiated in clinical studies.
Furthermore, the human studies reviewed in this essay have several limitations. The study by S.C. Conrad et al. involved 78 subjects; however, only eight of them were in the soy diet group [30]. The sample size in the soy diet group is too small and the difference of sample size between the soy and non-soy diet group is significant. This difference influences the significance of this study. In addition, Fort et al. pointed out there may be an existing association of feeding on soy-based infant formulas in early life and autoimmune thyroid disease in a case control study [32]. However, the reason for choosing soy-based infant formulas is a sensitivity or allergy to cow’s milk formulas, which means the children are more likely to have autoimmune disorders. The study also pointed out that 34 out of 189 subjects (approximately 18 percent) were fed with soy-based infant formulas, however, only 0.5 to 1.0 percent of infants have allergies in the United States. Therefore, the subjects in this study cannot represent common conditions. Additionally, Fort et al. also supposed isoflavones first inhibited TPO activity and then possibly increased the amount of thyroid hormones, which could trigger autoimmune thyroid disease [32] but this assumption has not been confirmed yet.
Therefore, animal studies indicate that the isoflavones in soy could inhibit TPO activity, and under the conditions of iodine deficiency, may cause hypothyroidism. However, the goitrogenic effects of isoflavones have not been substantiated in clinical studies, and the goitrogenic effect of physiological doses of isoflavones has not been illustrated in either animal experiments or clinical observations.
5.2   Suggestions for Further Study
So far, studies concerning the effects of isoflavones in soy-based formula on thyroid function among infants are very limited. Existing studies suggest further investigations of goiterogenic effects of isoflavones and effects of autoimmune thyroiditis in children fed with soy-based formulas. 
The researches suggest selecting a better animal model will be much more helpful to translate the data and results to humans. Currently, mammalian species, rats, mouse, piglets, are used as animal models [1]. Characterizing the absorption and metabolism of soy isoflavones in possible animal models is an ongoing area of further investigation.  In addition, in order to better understand the effects of isoflavones in soy-based formulas on thyroid function, animals should be fed with a soy-based diet instead of isolated isoflavones.
As for infant or children’s studies in the future, not only retrospective but also prospective studies are needed to better investigate how soy-based infant formulas may be affecting human thyroid function. Retrospective case-control studies have been conducted in the past; however, the sample size should be enlarged and subjects should be recruited from various geographical areas. If these samples could better represent the common situations in the United States, the studies could have much more significance. In addition, prospective studies are also needed. Prospective studies, which monitor the infants who are feeding on soy-based infant formulas currently, should not only focus on the short-term results but also monitor long-term effects on the thyroid function. Currently, there is a paucity of data regarding randomized controlled trials of infant formulas. In an ideal situation, a longitudinal study could be conducted where subjects are fed with soy-based or cow’s milk formulas randomly. However, there are many challenges that come with such a randomized controlled trial. It is believed that very few mothers would be willing to let their babies participate in such a randomized study, which could involve some ethical problems. Additionally, it is very difficult to preserve blinding because of the obviously different smell and taste of soy-based and cow’s milk formulas. Thus, a prospective cohort study may be another choice. In this cohort study, researchers would recruit healthy infants and separate them into two different groups depending on the soy-based formulas or cow’s milk formulas they are consuming, and then follow them to observe and compare their short-term and long-term thyroid functions. Although it is difficult to recruit a group of healthy infants feeding on soy-based formulas, it is not impossible to do this. One reason parents choose the soy-based infant formulas is that they want to raise their baby as a vegan. So the healthy subjects in the soy-based formulas feeding group could be selected from those vegan families. Undoubtedly, these studies are expensive and time-consuming. Therefore, funding and human resources are essential. 
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